NT-3
Selected indexed studies
- Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? (Expert Opin Ther Targets, 2020) [PMID:33141605]
- AAV1.NT-3 gene therapy prevents age-related sarcopenia. (Aging (Albany NY), 2023) [PMID:36897179]
- AAV1.tMCK.NT-3 gene therapy improves phenotype in Sh3tc2(-/-) mouse model of Charcot-Marie-Tooth Type 4C. (Brain Commun, 2024) [PMID:39544702]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? (2020) pubmed
- AAV1.NT-3 gene therapy prevents age-related sarcopenia. (2023) pubmed
- AAV1.tMCK.NT-3 gene therapy improves phenotype in Sh3tc2(-/-) mouse model of Charcot-Marie-Tooth Type 4C. (2024) pubmed
- NT-3. Takeda/Regeneron/Amgen. (2001) pubmed
- AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. (2022) pubmed
- AAV1.NT-3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia. (2023) pubmed
- NT-3 Combined with TGF-β Signaling Pathway Enhance the Repair of Spinal Cord Injury by Inhibiting Glial Scar Formation and Promoting Axonal Regeneration. (2024) pubmed
- Overexpression of NT-3 in the hippocampus suppresses the early phase of the adult neurogenic process. (2023) pubmed
- Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment. (2023) pubmed
- Downregulated NT-3 and PI3K/AKT signaling pathway mediates arsenic-induced apoptosis in hippocampal neurons in vivo and in vitro. (2025) pubmed